BVNKF:OTCMKTS
Bavarian Nordic A/S
$36.06
0.00%
(0.00) 1D
Okt 8, 3:46:25 PM GMT-4 · USD
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa BVNKF...
Mkt. cap
2.83B
Avg. na dami
14.00
Dami
0.00
Mataas nang 52-wk
$37.22
Mababa nang 52-wk
$27.69
Beta
1.46
Mga natitirang share
79.26M
Bilang ng mga empleyado
2K
Mkt. cap
2.83B
Avg. na dami
14.00
Dami
0.00
Mataas nang 52-wk
$37.22
Mababa nang 52-wk
$27.69
Beta
1.46
Mga natitirang share
79.26M
Bilang ng mga empleyado
2K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Bloomberg.com
·
1 oras ang nakalipas
European Shares Outperform S&P 500 Amid Defensive Tilt From AI
The Motley Fool
·
4 araw ang nakalipas
The S&P 500 Just Hit a Record High -- Here's How Much Higher It Can Climb, According to the Wall Street Consensus
Reuters
·
1 buwan ang nakalipas
S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
TheStreet
·
1 buwan ang nakalipas
UBS revamps S&P 500 target for rest of 2026
Profile
Bavarian Nordic A/S is a Danish biotechnology company focused on the development, manufacturing and commercialization of vaccines. The company is headquartered in Hellerup, Denmark, with manufacturing facilities in Kvistgård, Denmark and Thörishaus near Bern, Switzerland. The company has research and development facilities in Martinsried, Germany, as well as offices in USA, Canada, and France. The company uses viral vectors and virus-like particles in its research and development.
In July 2025, the company agreed to be acquired by private equity firms Permira and Nordic Capital for 19 billion kr. However, in November, the acquisition failed to gain sufficient support from Bavarian Nordic's shareholders, leading to its termination.
In 2026, Bavarian Nordic was ranked second in Time Magazine's World Most Impactful Companies. Wikipedia
Tungkol sa Bavarian Nordic A/S